1. Home
  2. PCB vs NGNE Comparison

PCB vs NGNE Comparison

Compare PCB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCB Bancorp

PCB

PCB Bancorp

HOLD

Current Price

$24.08

Market Cap

344.5M

Sector

Finance

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$27.21

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCB
NGNE
Founded
2003
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
344.5M
327.8M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
PCB
NGNE
Price
$24.08
$27.21
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$24.50
$63.57
AVG Volume (30 Days)
21.7K
148.2K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
3.67%
N/A
EPS Growth
48.28
0.93
EPS
2.58
N/A
Revenue
$2,899,000.00
N/A
Revenue This Year
$13.73
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$9.23
N/A
Revenue Growth
4.51
N/A
52 Week Low
$19.25
$11.78
52 Week High
$24.99
$37.27

Technical Indicators

Market Signals
Indicator
PCB
NGNE
Relative Strength Index (RSI) 62.67 65.32
Support Level $21.12 $19.40
Resistance Level $24.99 $29.05
Average True Range (ATR) 0.59 1.88
MACD -0.03 0.45
Stochastic Oscillator 55.18 81.15

Price Performance

Historical Comparison
PCB
NGNE

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: